🇺🇸 FDA
Patent

US 10683363

Targeting intracellular target-binding determinants with intracellular antibodies

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 10683363 (Targeting intracellular target-binding determinants with intracellular antibodies) held by The United States of America as represented by the Department of Veteran Affairs expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as represented by the Department of Veteran Affairs
Grant date
Tue Jun 16 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K39/39558